Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention

American Journal of Hematology

Volumn 87, Issue 2, 2012, Pages 221-223

  Kwiatkowski, Janet L ^a   Cohen, Alan R ^a   Garro, Julian ^b   Alvarez, Ofelia ^c   Nagasubramanian, Ramamorrthy ^d   Sarnaik, Sharada ^e   Thompson, Alexis ^f   Woods, Gerald M ^g   Schultz, William ^h   Mortier, Nicole ^h   Lane, Peter ⁱ   Mueller, Brigitta ^h   Yovetich, Nancy ^b   Ware, Russell E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Rho   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NEMOURS CHILDREN S HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOGLOBIN; HYDROXYUREA; IRON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LETTER; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; SICKLE CELL ANEMIA; STROKE; THALASSEMIA; TREATMENT DURATION;

ADOLESCENT; ANEMIA, SICKLE CELL; BENZOATES; BLOOD TRANSFUSION; CHELATION THERAPY; CHILD; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; SECONDARY PREVENTION; STROKE; TRIAZOLES; YOUNG ADULT;

EID: 84855974931     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22228     Document Type: Letter

References (21)

1. Fung EB, Harmatz PR, Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 2008; 48: 1971-1980.
2. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995; 126: 896-899.
3. Borgna-Pignatti C, De Stefano P, Zonta L, et al. Growth and sexual maturation in thalassemia major. J Pediatr 1985; 106: 150-155.
4. Jean G, Terzoli S, Mauri R, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child 1984; 59: 67-70.
5. Zurlo MG, De Stefano P, Borgna-Pignatti C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2: 27-30.
6. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135: 574-582.
7. Wood JC. Cardiac iron across different transfusion-dependent diseases. Blood Rev 2008; 22( Suppl 2): S14-S21.
8. Cohen AR, Martin MB, Silber JH, et al. A modified transfusion program for prevention of stroke in sickle cell disease. Blood 1992; 79: 1657-1661.
9. Cabibbo S, Fidone C, Garozzo G, et al. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfus Apher Sci 2005; 32: 315-321.
10. Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood 1994; 83: 1136-1142.
11. Ware R, Schultz W, Yovetich N. Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer 2011; 57: 1011-1017.
12. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
13. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
14. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574-578.
15. Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993; 42: 81-85.
16. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96: 76-79.
17. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels. Pediatr Blood Cancer 2008; 50: 62-65.
18. Adamkiewicz TV, Abboud MR, Paley C, et al. Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 2009; 114: 4632-4638.
19. Cappellini MD, Cohen A, Eleftheriou A, et al. The Thalassemia International Federation Guidelines for the Clinical Management of Thalassemia. Nicosia: Thalassemia International Federation; 2008.
20. Hilliard LM, Williams BF, Lounsbury AE, et al. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28-35.
21. Carrara P, Balocco M, Pinto V, et al. Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: A long-term follow-up. Am J Hematol 2010; 85: 974.